日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1.

FLT201 是一种新型的肝脏靶向 AAV 基因治疗候选药物,用于治疗 1 型戈谢病。

Comper Fabrizio, Miranda Carlos J, Liou Benjamin, Dodev Tihomir, Jeyakumar Jey M, Canavese Miriam, Cocita Clement, Khoshrou Khashayar, Tiscornia Gustavo, Chisari Elisa, Stotter Emmaline, Shehu Erald, Sridharan Sudharsan, Yu I-Mei, Pandya Jalpa, Khinder Jaminder, Northcott Natalie, Kalcheva Petya, Correia Samantha, Sun Ying, Dane Allison P, Sheridan Rose, Nathwani Amit C, Corbau Romuald

3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes

3550 了解肝细胞癌治疗和结果中的种族差异

Cunningham, Sharon C; Kok, Cindy Y; Dane, Allison P; Carpenter, Kevin; Kizana, Eddy; Kuchel, Philip W; Alexander, Ian E; Parthasarathy, P; Khan, M; Nephew, Lauren Devore; Rawl, Susan; Chalasani, Naga

Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation.

成年小鼠肝脏中游离型rAAV基因组持续存在的性别二态性模式及其与肝细胞增殖的相关性

Dane Allison P, Cunningham Sharon C, Graf Nicole S, Alexander Ian E